ADMA

ADMA Biologics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/06/26

Business Summary

ADMA Biologics operates as a plasma-derived biologics company, generating revenue by collecting plasma and manufacturing specialized immune globulin therapies. Its moat stems from vertical integration—controlling plasma collection and production—which enhances margin control and supply reliability. Regulatory complexity and capital intensity create barriers to entry, limiting smaller competitors. Cash generation is driven by high-margin biologic therapies supported by durable demand within specialized patient populations, allowing operating margins to scale as production efficiency improves.

VALUATION

P/E

16.2

Market Cap ($M USD)

$2,310

Forward P/E

7

PEG

0.3

PRICE TO SALES

4.7

PRICE TO BOOK

4.8

EV / EBITDA

11.6

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

$0.62

Next Year EPS Growth Estimate

$1.38

Next Year Revenue Growth Estimate

22.10%

Return on Equity (ROE)

30.80%

Operating Margin

37.50%

Debt-to-Equity

0.2

Piotroski F-Score

6

Altman Z-Score

11.7

Return on Invested Capital (ROIC)

30.60%%

Current Ratio

6.7

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At 16.2x earnings and just 7x forward earnings, ADMA screens as a textbook GARP dislocation. A 0.3 forward PEG combined with a 30.60% ROIC and 22.10% ROE signals a business generating real economic profit that the market is pricing like a slow grower. The balance sheet is fortress-level safe with an Altman Z-Score of 11.7 and a 6.7 current ratio, eliminating solvency risk from the equation. When you pair that safety with a 30.80% operating margin and compressing forward multiple, this looks less like a speculative biotech and more like a cash-generating compounder the market hasn’t fully repriced.

AI Exposure / Tech Reliance

As a biotechnology company in Healthcare, ADMA operates in a sector increasingly enhanced by AI-driven drug development, data analytics, and manufacturing optimization. The combination of high operating margins (30.80%) and strong ROIC (30.60%) suggests operational scalability, which aligns well with tech-enabled efficiency gains. Biotech firms that integrate data science into plasma sourcing, production, and clinical processes tend to widen margins further, reinforcing resilience.

The Bull Case

This is where a disciplined GARP investor leans in. A 30.60% ROIC against a 4.8x price-to-book ratio and 4.7x price-to-sales ratio indicates capital is being deployed efficiently enough to justify premium multiples. The Piotroski F-Score of 6 signals fundamentally sound operations, not distress-driven earnings. With 22.10% ROE, 30.80% operating margins, and a forward P/E of 7, you’re effectively buying a high-return business at a compressed growth multiple. Add in a conservative 37.50% debt-to-equity ratio and massive liquidity buffer via a 6.7 current ratio, and institutions looking for profitable biotech exposure have a mathematically compelling entry point.

The Bear Case

There are inconsistencies that demand scrutiny. EPS is listed at 11.6 while next year’s estimate is $0.62, which implies either normalization risk or earnings volatility—hardly trivial for a biotech. The PEG forward at 0.3 looks attractive, but “Sales Growth Next Year” of $1.38 lacks clarity, and without a clean growth trajectory, multiple compression could be justified. Institutional Ownership at $30.00 and a Consensus Rating of 13.30% raise questions about sentiment and sponsorship strength, and without a listed short percentage of float, it’s impossible to gauge whether sophisticated investors are positioning against it.

Market Sentiment & Smart Money

Short Interest %

13.30%

Analyst Consensus

1.67

Average Analyst Price Target

$30.00

Institutional Ownership %

94.70%

1-Year Beta

1.36

Insider Buying % (6 Mo)

2.60%%

Distance to 52-Week High

37.80%%

Distance to 52-Week Low

134.50%%